Last reviewed · How we verify
Vertanical GmbH — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| VER-01 | VER-01 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| Opioid therapy | Opioid therapy | phase 3 | Opioid | Opioid receptors | Pain management |
Therapeutic area mix
- Diabetes · 1
- Pain management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ADvantage Therapeutics · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
- AO GENERIUM · 1 shared drug class
- Abbott · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Aciex Therapeutics, Inc. · 1 shared drug class
- 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Vertanical GmbH:
- Vertanical GmbH pipeline updates — RSS
- Vertanical GmbH pipeline updates — Atom
- Vertanical GmbH pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Vertanical GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vertanical-gmbh. Accessed 2026-06-10.